Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences, a skin cancer diagnostics company, will present two significant studies at the American Academy of Dermatology’s Virtual Meeting from April 23-25, 2021. These studies focus on their genomic tests: DecisionDx-Melanoma and DecisionDx-SCC. The DecisionDx-Melanoma study highlights a Class 2B result as a critical predictor of recurrence in stage I melanoma patients, with a recurrence rate of 20.4%. The DecisionDx-SCC study indicates that incorporating this genomic risk profiling can significantly reduce patient sample sizes needed for clinical trials, optimizing healthcare costs and patient management.
Castle Biosciences (Nasdaq: CSTL) showcased its gene expression profile tests at the Dermatology Nurses' Association 2021 Annual Convention. The presentations included the DecisionDx®-Melanoma, which predicts cutaneous melanoma risk, and DecisionDx®-SCC for high-risk squamous cell carcinoma. Data showed DecisionDx-Melanoma's robust predictive ability for recurrence-free survival, outperforming traditional metrics. The DecisionDx DiffDx®-Melanoma enhances diagnostic precision for challenging lesions. The tests aim to improve treatment decisions and patient outcomes by using tumor biology insights.
Castle Biosciences, Inc. (Nasdaq: CSTL) presented data on its skin cancer gene expression tests at the 10th World Congress of Melanoma and 17th EADO Congress. The company showcased its DecisionDx-Melanoma, DecisionDx-SCC, and DecisionDx DiffDx-Melanoma tests, highlighting their effectiveness in predicting melanoma metastasis and improving risk assessment in cutaneous squamous cell carcinoma. Key findings included significant disease-free survival rates among different risk classes and validation of the tests' prognostic values, which may enhance patient management strategies.
Castle Biosciences (Nasdaq: CSTL) presented data on the integration of its DecisionDx-Melanoma test with clinicopathologic features at the 10th World Congress of Melanoma. The test, which predicts sentinel lymph node (SLN) positivity, utilizes an artificial intelligence-based algorithm called i31-GEP, validated in a cohort of 1,674 patients. Key findings include a high negative predictive value of 98% and reclassification of 63% of patients originally at 5-10% SLN positivity risk. These results aim to refine risk assessment and potential pre-surgical decision-making for melanoma patients.
Castle Biosciences (Nasdaq: CSTL) has announced positive results from an independent study published in the American Journal of Surgery, demonstrating the effectiveness of its DecisionDx®-Melanoma test in predicting patient outcomes for cutaneous melanoma. The study, involving 383 patients, showed that high-risk results correlated with increased rates of sentinel lymph node positivity and higher recurrence rates. The findings emphasize the test's ability to provide significant prognostic information beyond traditional staging methods, thereby aiding treatment decisions.
Castle Biosciences (Nasdaq: CSTL) announced the publication of long-term outcomes data for its DecisionDx-Melanoma test, aimed at predicting risks associated with cutaneous melanoma. Published in JCO® Precision Oncology, the study verifies the test's effectiveness in identifying recurrence risk in early-stage melanoma patients, thus extending previous findings. Notably, the test serves as a significant predictor of recurrence-free, distant metastasis-free, and overall survival, enhancing the predictive power when combined with AJCC staging.
Castle Biosciences (Nasdaq: CSTL) announced a partnership with the Melanoma Research Foundation to present the 'Ask the Expert' Managing Melanoma webinar series during April 2021. This initiative aims to enhance awareness and education regarding melanoma, featuring expert discussions on topics such as tumor genetics and gene expression profiling. The webinars will be broadcast live on the MRF Facebook page, providing vital resources for patients and promoting early detection and prevention of melanoma.
Castle Biosciences (Nasdaq: CSTL) has announced that CEO Derek Maetzold will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. ET. The presentation will focus on the company's innovative genomic tests aimed at improving cancer treatment decisions for patients with skin cancers. A live audio webcast will be accessible via Castle Biosciences' website, with a replay available for two weeks post-event.
Castle specializes in personalized genomic information for various dermatologic cancers, enhancing decision-making for physicians and patients.
Castle Biosciences (Nasdaq: CSTL) announced a study showing increasing use of its DecisionDx®-Melanoma test among dermatologists for managing melanoma patients. The study featured responses from 589 U.S. dermatologists, revealing that 45% ordered the test in the last year, with 82% likely to do so moving forward. DecisionDx-Melanoma significantly influences treatment decisions, particularly for early-stage melanomas, with a Class 1A result showing a 96.8% 5-year recurrence-free survival rate. Dermatologists reported benefits for patients, such as reduced anxiety and improved treatment personalization.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its financial results for 2020, achieving revenues of $62.6 million, up 21% from 2019. The company expanded its product offerings to three skin cancer tests, increasing its U.S. total addressable market to $2 billion. The integrated AI-based DecisionDx-Melanoma test was launched, promising improved risk predictions. However, operating cash flow dropped to $9.9 million, and fourth-quarter revenue slightly declined to $17.3 million. With $410 million in cash, the company remains positioned for growth, predicting an additional $3.6 billion market opportunity.